Dynavax Technologies (NASDAQ:DVAX – Get Free Report)‘s stock had its “outperform” rating reaffirmed by William Blair in a note issued to investors on Friday,RTT News reports. William Blair also issued ...
Citizens JMP raised the firm’s price target on Dynavax (DVAX) to $33 from $29 and keeps an Outperform rating on the shares. Dynavax reported ...
Life sciences investment firm Deep Track Capital is launching a board fight at Dynavax Technologies , pressing for new directors to prioritize the development of the company's hepatitis B vaccine ...
During the last three months, 4 analysts shared their evaluations of Dynavax Technologies DVAX, revealing diverse outlooks from bullish to bearish. The following table encapsulates their recent ...
JMP Securities analyst Jason Butler reiterated a Buy rating on Dynavax (DVAX – Research Report) today and set a price target of $33.00. The ...
Deep Track Capital, LP, (together with its affiliates, “Deep Track” or “we”), one of the largest shareholders of Dynavax Technologies Corporation (NAS ...
3don MSN
Q4 2024 Management View CEO Ryan Spencer highlighted the company’s record HEPLISAV-B product revenue in Q4 and 2024, achieving profitability and implementing a share repurchase plan. Looking ahead, ...
HEPLISAV-B net product revenue is expected in the range of $305M to $325M Discover the Best Stocks and Maximize Your Portfolio: See what ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback